Scientific Posters from AACR 2017

The AACR Annual Meeting is a forum for Charles River scientists to showcase key findings from independent research and collaborative efforts with top scientists from across the globe. During this year’s meeting, Charles River scientists from multiple sites and scientific disciplines presented scientific posters either independently or collaboratively with our clients.

Monday, April 3, 2017

Tumor regression in novel triple therapy BRAF mutant metastatic melanoma patient-derived preclinical models
Antoneicka L. Harris1, Michael Thompson2, Svetomir Markovic2, William Durham3, Louis Dawson3, Daniel Small3, John A. Copland, III1
1Mayo Clinic, Jacksonville, FL; 2Mayo Clinic, Rochester, MN; 3Charles River Discovery, Morrisville, NC

Whole-exome somatic mutation analysis of mouse cancer models and implications for preclinical immunomodulatory drug development
Bruno Zeitouni1, Cordula Tschuch1, Jason M. Davis2, Anne-Lise Peille1, Yana Raeva1, Manuel Landesfeind1, Sheri Barnes2, Julia B. Schüler1
1Oncotest GmbH, Freiburg, Germany; 2Charles River Discovery, Morrisville, NC

Tuesday, April 4, 2017

Humanized single mouse trial: A preclinical platform feasible for immune-oncology drug screening and translational biomarker development
Daniel Bug1, Eva Oswald2, Anne Grote3, Anne-Lise Peille2, Gabriele Niedermann4, Dorit Merhof1, Friedrich Feuerhake3, Julia B. Schüler2
1RWTH Aachen University, Aachen, Germany; 2Oncotest GmbH, Freiburg, Germany; 3Hannover Medical School, Hannover, Germany; 4Medical Center Freiburg, Freiburg, Germany

Influence of the injection site on the dissemination pattern and drug sensitivity of patient derived leukemia cells in vivo
Julia B. Schüler1, Eva Oswald1, Gabriele Greve2, Dorothee Lenhard1, Kerstin Klingner1, Milena Pantic2, Michael Luebbert2
1Oncotest GmbH, Freiburg, Germany; 2Medical Center Freiburg, Freiburg, Germany

The Pharmacological Effects of Estrogen Receptor alpha Y537S and D538G Mutations
Steven J. Hartman1, Tracy Kleinheinz1, Jonathan White2, Stephen Daly2, Ria Goodwin2, Wei Zhou1, Jun Liang1, Xiaojing Wang1, Daniel F. Ortwine1, Lori Friedman1, Martin O’Rourke2, Ciara Metcalfe1, Robert A. Blake1
1Genentech, Inc., South San Francisco, CA; 2Charles River Laboratories, Harlow, United Kingdom

Wednesday, April 5, 2017

In vitro PDX models: 3D cultured patient-derived tumors for compound evaluation
Sander Basten1, Bram Herpers1, Julia Schueler2, Torsten Giesemann2, Leo S. Price1
1OcellO B.V., Leiden, Netherlands; 2Charles River Laboratories, Freiburg, Germany